These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 34779140)

  • 21. Prevalence of Frailty and Associations with Oral Anticoagulant Prescribing in Atrial Fibrillation.
    Sanghai SR; Liu W; Wang W; Rongali S; Orkaby AR; Saczynski JS; Rose AJ; Kapoor A; Li W; Yu H; McManus DD
    J Gen Intern Med; 2022 Mar; 37(4):730-736. PubMed ID: 33948795
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Trends in initiation of direct oral anticoagulant therapies for atrial fibrillation in a national population-based cross-sectional study in the French health insurance databases.
    Huiart L; Ferdynus C; Renoux C; Beaugrand A; Lafarge S; Bruneau L; Suissa S; Maillard O; Ranouil X
    BMJ Open; 2018 Mar; 8(3):e018180. PubMed ID: 29602837
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation and bioprosthetic valves: A meta-analysis.
    Yokoyama Y; Briasoulis A; Ueyama H; Mori M; Iwagami M; Misumida N; Takagi H; Kuno T
    J Thorac Cardiovasc Surg; 2023 Jun; 165(6):2052-2059.e4. PubMed ID: 34417050
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Outcomes Among Patients With Atrial Fibrillation and Appropriate Anticoagulation Control.
    Bonde AN; Staerk L; Lee CJ; Vinding NE; Bang CN; Torp-Pedersen C; Gislason G; Lip GYH; Olesen JB
    J Am Coll Cardiol; 2018 Sep; 72(12):1357-1365. PubMed ID: 30213328
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real-world persistence with direct oral anticoagulants (DOACs) in naïve patients with non-valvular atrial fibrillation.
    Ferroni E; Gennaro N; Costa G; Fedeli U; Denas G; Pengo V; Corti MC
    Int J Cardiol; 2019 Aug; 288():72-75. PubMed ID: 31043323
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of Vitamin K and Non-Vitamin K Oral Anticoagulant Use and Cancer Incidence in Atrial Fibrillation Patients.
    Iftimi AA; Rodríguez-Bernal CL; Peiró S; Bonanad S; Ferrero-Gregori A; Hurtado I; García-Sempere A; Sanfélix-Gimeno G
    Clin Pharmacol Ther; 2022 Jan; 111(1):200-208. PubMed ID: 34242404
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Uninterrupted anticoagulation during catheter ablation for atrial fibrillation: no difference in major bleeding and stroke between direct oral anticoagulants and vitamin K antagonists in an updated meta-analysis of randomised controlled trials.
    Brockmeyer M; Lin Y; Parco C; Karathanos A; Krieger T; Schulze V; Heinen Y; Bejinariu A; Müller P; Makimoto H; Kelm M; Wolff G
    Acta Cardiol; 2021 May; 76(3):288-295. PubMed ID: 32056498
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stroke severity in patients with preceding direct oral anticoagulant therapy as compared to vitamin K antagonists.
    Auer E; Frey S; Kaesmacher J; Hakim A; Seiffge DJ; Goeldlin M; Arnold M; Fischer U; Jung S; Meinel TR
    J Neurol; 2019 Sep; 266(9):2263-2272. PubMed ID: 31165232
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oral Anticoagulant Adequacy in Non-Valvular Atrial Fibrillation in Primary Care: A Cross-Sectional Study Using Real-World Data (Fantas-TIC Study).
    Dalmau Llorca MR; Aguilar Martín C; Carrasco-Querol N; Hernández Rojas Z; Forcadell Drago E; Rodríguez Cumplido D; Pepió Vilaubí JM; Castro Blanco E; Gonçalves AQ; Fernández-Sáez J
    Int J Environ Res Public Health; 2021 Feb; 18(5):. PubMed ID: 33668315
    [No Abstract]   [Full Text] [Related]  

  • 30. [Coumarin or DOAC in frail elderly patients with atrial fibrillation?].
    Joosten LPT; van Doorn S; Hemels MEW; Huisman MV; Rutten FH; Geersing GJ
    Ned Tijdschr Geneeskd; 2024 Jan; 168():. PubMed ID: 38525862
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acute Ischemic Stroke Outcome and Preceding Anticoagulation: Direct Oral Anticoagulants Versus Vitamin K Antagonists.
    Tavares SF; Ferreira I; Chaves V; Flores L; Correia C; Almeida J; Fonseca L; Castro Chaves P
    J Stroke Cerebrovasc Dis; 2020 Apr; 29(4):104691. PubMed ID: 32067853
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early introduction of direct oral anticoagulants in cardioembolic stroke patients with non-valvular atrial fibrillation.
    Cappellari M; Carletti M; Danese A; Bovi P
    J Thromb Thrombolysis; 2016 Oct; 42(3):393-8. PubMed ID: 27329483
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Initiation and continuation of oral anticoagulant prescriptions for stroke prevention in non-valvular atrial fibrillation: A cohort study in primary care in France.
    Collings SL; Vannier-Moreau V; Johnson ME; Stynes G; Lefèvre C; Maguire A; Asmar J; Bizouard G; Duhot D; Mouquet F; Fauchier L
    Arch Cardiovasc Dis; 2018 May; 111(5):370-379. PubMed ID: 29398546
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term vitamin K antagonists treatment patterns of Non-Valvular Atrial Fibrillation (NVAF): a population-based cohort study.
    Renoux C; Coulombe J; Suissa S
    BMC Cardiovasc Disord; 2016 May; 16():84. PubMed ID: 27160254
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Using the Case-Crossover Design to Assess Short-Term Risks of Bleeding and Arterial Thromboembolism After Switching Between Oral Anticoagulants in a Population-Based Cohort of Patients With Atrial Fibrillation.
    Hellfritzsch M; Wang SV; Grove EL; Gagne JJ; Hallas J; Pottegård A
    Am J Epidemiol; 2020 Dec; 189(12):1467-1477. PubMed ID: 32639512
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of non-adherence to direct oral anticoagulants amongst Swedish patients with non-valvular atrial fibrillation: results from a real-world cost-utility analysis.
    Blomström Lundqvist C; Själander S; Garcia Rodriguez LA; Åkerborg Ö; Jin G; Caleyachetty A; Huelsebeck M; Bowrin K; Schaefer B; Mahdessian H; Hofmeister L; Levin LÅ
    J Med Econ; 2022; 25(1):1085-1091. PubMed ID: 35997241
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Oral anticoagulation in atrial fibrillation: What is the guideline for using new drugs?].
    Ibáñez Pérez de Viñaspre JA; Gómez Bitrian J; Royo Hernández R; de Azúa Jiménez M; Marco López C; Urieta González L
    Semergen; 2018; 44(5):297-303. PubMed ID: 28867369
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oral anticoagulant persistence in patients with non-valvular atrial fibrillation: A cohort study using primary care data in Germany.
    Collings SL; Lefèvre C; Johnson ME; Evans D; Hack G; Stynes G; Maguire A
    PLoS One; 2017; 12(10):e0185642. PubMed ID: 29016695
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of a tool to identify patients' preference for vitamin K antagonist or direct oral anticoagulant therapy.
    Zolfaghari S; Harenberg J; Froelich L; Wehling M; Weiss C
    Semin Thromb Hemost; 2014 Feb; 40(1):121-8. PubMed ID: 24381153
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Continuous and minimally-interrupted direct oral anticoagulant are both safe compared with vitamin K antagonist for atrial fibrillation ablation: An updated meta-analysis.
    Ha FJ; Barra S; Brown AJ; Begley DA; Grace AA; Agarwal S
    Int J Cardiol; 2018 Jul; 262():51-56. PubMed ID: 29606512
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.